| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
IC50: 15 μM (MIF2)[1]
MIF2 (Macrophage Migration Inhibitory Factor 2). |
|---|---|
| ln Vitro |
R110 is a competitive MIF2 tautomerase inhibitor with an IC50 of 15 microM. It directly binds to the active site of MIF2 and blocks its enzymatic activity. In cellular assays, R110 reduces MIF2-dependent pro-inflammatory cytokine production and may inhibit cancer cell proliferation and migration.
|
| ln Vivo |
No in vivo activity data for R110 is publicly available. For MIF2 inhibitors in general, in vivo efficacy is evaluated in mouse models of cancer or inflammation. MIF2 inhibition may reduce tumor growth, metastasis, and inflammatory responses, but specific data for R110 is not reported.
|
| Enzyme Assay |
Not available. A generic MIF2 tautomerase assay is performed. Recombinant human MIF2 protein (50-100 nM) is pre-incubated with R110 (0.1 microM-1 mM) in assay buffer (50 mM sodium phosphate pH 7.2, 0.5 mM EDTA, 0.1 mM DTT, 0.1% BSA) for 15-30 min at 25degC. Substrate (L-dopachrome methyl ester, 0.5 mM) is added, and the tautomerase reaction is monitored by absorbance decrease at 475 nm over 2-5 min using a spectrophotometer. IC50 (15 microM) is calculated from the inhibition curve. Competitive inhibition is confirmed by Lineweaver-Burk plots with varying substrate concentrations.
|
| Cell Assay |
Human cancer cell lines (e.g., A549 lung cancer, MCF-7 breast cancer, or HeLa cervical cancer) are seeded in 96-well plates (5×103/well) in DMEM with 10% FBS. After 24 h, cells are treated with R110 (0-100 microM) for 48-72 h. Cell viability is assessed by MTT or CellTiter-Glo assay. For cytokine production assays, THP-1 monocytes are differentiated into macrophages with PMA (50 ng/mL, 48 h). Cells are primed with LPS (100 ng/mL, 4 h), then treated with R110 (0-100 microM) and MIF2 (10 ng/mL). After 24 h, supernatants are collected for TNF-alpha and IL-6 ELISA. Cell migration is assessed using scratch wound healing assay: confluent cell monolayers are scratched with a pipette tip, and wound closure is monitored for 24-48 h in the presence of R110 (0-100 microM).
|
| Animal Protocol |
No animal protocol is published. Generic protocol for MIF2 inhibitors in tumor xenograft models: female BALB/c nude mice (6-8 weeks) are injected subcutaneously with A549 or H460 human lung cancer cells (5×10⁶) in 100 microL PBS. When tumors reach ~100-150 mm3, mice are randomized (n=8/group). R110 is administered intraperitoneally at 50-100 mg/kg daily or every other day for 2-3 weeks. Tumor volumes are measured by calipers every 3 days. At termination, tumors are weighed, and tumor growth inhibition (TGI%) is calculated. Tumors are analyzed by Western blot for MIF2 expression and immunohistochemistry for Ki-67 and cleaved caspase-3. Serum is collected for cytokine analysis.
|
| ADME/Pharmacokinetics |
No PK data reported for R110. Generic PK for small molecule MIF inhibitors: male SD rats (200-250 g, n=3-4 per time point) receive single IV (5 mg/kg) and oral (25 mg/kg) doses of R110. Blood samples are collected at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 18, and 24 h. Plasma is separated and analyzed by LC-MS/MS. PK parameters: t1/2 (2-6 h), Cmax (0.5-5 microM), Tmax (0.5-2 h), AUC, CL (10-30 mL/min/kg), Vd (1-3 L/kg), and oral bioavailability (20-50%).
|
| Toxicity/Toxicokinetics |
No toxicity data reported. Generic acute toxicity study: ICR mice (5/sex/group) receive a single intraperitoneal or oral dose of R110 at 50, 150, 300, 600 mg/kg. Animals are observed for 14 days for mortality and clinical signs (body weight, food consumption, behavior, coat condition). At termination, gross necropsy and histopathology of major organs (liver, kidney, spleen, heart, lung, brain, GI tract) are performed. MTD (maximum tolerated dose) and NOAEL (no observed adverse effect level) are determined.
|
| References | |
| Additional Infomation |
R110 is a research-grade competitive MIF2 tautomerase inhibitor. MIF2 is a less-studied homolog of MIF, and R110 serves as a valuable tool for investigating MIF2-specific biological functions. R110 is not FDA-approved and has not entered clinical trials. Its moderate potency (IC50 15 microM) makes it suitable for mechanistic studies but may require higher concentrations for in vivo efficacy. The compound is used exclusively in laboratory research to study MIF2's role in cancer progression, inflammation, and immune modulation.
|
| Molecular Formula |
C15H17CLN2OS
|
|---|---|
| Molecular Weight |
308.826281309128
|
| Exact Mass |
308.075
|
| CAS # |
1985622-33-0
|
| PubChem CID |
134152941
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
4.6
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
20
|
| Complexity |
321
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1(N)SC(C2=CC=C(Cl)C=C2)=CC=1C(NCCCC)=O
|
| InChi Key |
IADRJQICSPVBQR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H17ClN2OS/c1-2-3-8-18-15(19)12-9-13(20-14(12)17)10-4-6-11(16)7-5-10/h4-7,9H,2-3,8,17H2,1H3,(H,18,19)
|
| Chemical Name |
2-amino-N-butyl-5-(4-chlorophenyl)thiophene-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (161.90 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2380 mL | 16.1901 mL | 32.3803 mL | |
| 5 mM | 0.6476 mL | 3.2380 mL | 6.4761 mL | |
| 10 mM | 0.3238 mL | 1.6190 mL | 3.2380 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
